ClinicalTrials.gg
Status unknownNCT06616233ENRICHUpdated Sep 27, 2024

Remote Ischaemic Conditioning (RIC) in Heart Failure

An interventional study of Remote Ischaemic Conditioning with exercise and Other: Remote Ischaemic Conditioning in Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes and Dilated Cardiomyopathy, sponsored by University of Leicester. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by University of Leicester · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test the impact of remote ischaemic conditioning combined with exercise on myocardial perfusion in patients with or at risk of heart failure

Read the detailed description

Heart failure (HF) is a disease which affects the heart's ability to pump or fill with blood. It can affect a person's quality of life and their ability to exercise. Recent work has shown that a reduction in the blood supply to the heart may contribute to the problem. It is therefore possible that improving the blood supply to the heart may help patients with HF. One possible way that this might be achieved is with a method called remote ischaemic conditioning (RIC). This involves placing a cuff on a person's arm (identical to a blood pressure cuff) and inflating it for a few minutes to reduce the blood flow in a person's arm. This is thought to release chemicals into the bloodstream which can have positive effects on the heart. This has been studied in patients with other forms of heart disease, but is yet to be tested properly in patients with heart failure. It is hypothesized that combining the RIC procedure with a low level of arm exercise may result in further improvements in the person's blood vessels and heart. This will be tested in a single-centre prospective study.

02

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Type 2 Diabetes
  • Dilated Cardiomyopathy
03

In context

Diabetes Mellitus, Type 2

9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.

This study's planned enrollment of 60 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

University of Leicester is the lead sponsor of 170 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Ability to provide written consent
  • clinical diagnosis of HFpEF (LVEF ≥50%; symptoms and signs of heart failure [HF] caused by a structural and/or functional abnormality, and at least one: elevated natriuretic peptides; ambulatory; BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL or hospitalised; BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL, and objective evidence of cardiogenic pulmonary or systemic congestion) OR stable type 2 diabetes (determined by formal diagnosis in hospital or GP case records with diagnostic oral glucose tolerance test or glycated haemoglobin level ≥6.5%) and with ACC/AHA stage B HF (structural disorder of the heart but no current or previous symptoms of HF) OR confirmed diagnosis of dilated cardiomyopathy

Exclusion criteria

Exclusion Criteria:

  • Absolute contraindications to MRI or contrast (e.g. severe claustrophobia, pregnancy, ferromagnetic implants, inability to lie flat, severe renal impairment eGFR\<30ml/min/m2)
  • Moderate to severe valvular heart disease
  • Confirmed coronary artery disease (>50% narrowing in any major epicardial coronary artery on invasive or computed tomography coronary angiography, previous myocardial infarction, previous percutaneous intervention or coronary bypass surgery)
  • Known arterial stenosis of the upper extremity
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Remote Ischaemic Conditioning with Exercise

    Participants will be randomised to receive remote ischaemic conditioning (RIC) with exercise involving a 4-week home-based programme of RIC with exercise . The exercise will involve handgrip exercise during the cuff deflation phase of RIC.

    Device: Remote Ischaemic Conditioning with exercise

  • Other
    Remote Ischaemic Conditioning

    Participants will receive remote ischaemic conditioning (RIC) without exercise involving a 4-week home-based programme of RIC.

    Device: Other: Remote Ischaemic Conditioning

Interventions

  • DeviceRemote Ischaemic Conditioning with exercise

    Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.

  • DeviceOther: Remote Ischaemic Conditioning

    Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.

06

What researchers measure

Primary outcomes

  1. Myocardial perfusion reserve

    myocardial perfusion reserve under adenosine stress as assessed by quantitative cardiovascular magnetic resonance (CMR)

    Time frame: 4 weeks

  2. Contraction strength in the cuff deflation phase of RIC

    contraction force achieved during cuff deflation phase, measured in Newtons

    Time frame: 1 day

  3. Hyperaemic myocardial blood flow

    myocardial blood flow under adenosine stress as assessed by quantitative cardiovascular magnetic resonance (CMR)

    Time frame: 4 weeks

Secondary outcomes

  1. Brachial artery flow mediated dilation

    endothelial function as assessed by vascular ultrasound

    Time frame: 4 weeks

  2. Skeletal muscle strength

    maximal handgrip strength (newtons)

    Time frame: 4 weeks

  3. Skeletal muscle endurance

    Isometric skeletal muscle endurance test assessed using handgrip dynamometer (sec)

    Time frame: 4 weeks

  4. Cardiopulmonary exercise test

    VO2 max for maximal aerobic capacity

    Time frame: 4 weeks

  5. Brachial artery maximal dilatory capacity

    endothelial function in response to Glyceryl trinitrate (GTN) as assessed by vascular ultrasound

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Glenfield Hospital
    Leicester, Leics LE3 9QP, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — no plan to share IPD

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06616233
Collaborators
Loughborough University
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Apr 8, 2024
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Sep 27, 2024

Study contacts

Jayanth Arnold, BMBCh DPhil
Contact
jra14@leicester.ac.uk
+44 1162583038
Aaron Wiseman
Contact
aw520@leicester.ac.uk
Jayanth R Arnold, BMBCh DPhil
principal investigator · University of Leicester

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion